Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 1,101–1,200 of 4,628
Corral, M., DeYoung, K., & Kong, A. M. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-01224-5 · Cited by 39
Chang, C., Lin, C., Lee, C., Chuang, H., Shih, F.-C., Wan, S.-W., Tai, C., & Chen, C. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114356 · Cited by 46
Ruigrok, M. J. R., Frijlink, H. W., Melgert, B. N., Olinga, P., & Hinrichs, W. L. J. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.01.003 · Cited by 45
Shimbori, C., Bellaye, P., Kolb, P., & Kolb, M. R. J. (2017) · Milestones in drug therapy · doi:10.1007/978-3-0348-0977-1_3 · Cited by 38
Self-citationGlaspole, I., Bonella, F., Bargagli, E., Glassberg, M. K., Caro, F. M., Stansen, W., Quaresma, M., Orsatti, L., & Bendstrup, E. M. (2021) · Respiratory Research · doi:10.1186/s12931-021-01695-y · Cited by 43
“Nintedanib is an approved treatment for IPF, which slows the progression of the disease by reducing the rate of decline in forced vital capacity (FVC) [8, 9].”
BackgroundInfluentialMattoo, H., & Pillai, S. S. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03874-y · Cited by 40
Guardela, B. J., Sun, J., Zhang, T., Xu, B., Balnis, J., Huang, Y., Ma, S., Molyneaux, P. L., Maher, T. M., Noth, I., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103439 · Cited by 39
“The use of 50-gene risk profiles could also support the rationale to investigate the use of IPF-targeted antifibrotic medications [27,28] to prevent shortand long-term sequela of COVID-19.”
Update on diagnosis and treatment of idiopathic pulmonary fibrosis
Martínez, J. A. B., Baldi, B. G., da Costa, C. H., Jezler, S. F. D. O., Lima, M. S., & Rufino, R. (2015) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132015000000152 · Cited by 43
Clinical characteristics of idiopathic pulmonary fibrosis patients according to their smoking status
Kishaba, T., Nagano, H., Nei, Y., & Yamashiro, S. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.03.89 · Cited by 37
Müller, T., Fay, S., Vieira, R. P., Karmouty‐Quintana, H., Cicko, S., Ayata, C. K., Zissel, G., Goldmann, T., Lungarella, G., Ferrari, D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16414 · Cited by 45
Pharmacological management of IPF
Borie, R., Justet, A., Beltramo, G., Manali, E. D., Pradère, P., Spagnolo, P., & Crestani, B. (2016) · Respirology · doi:10.1111/resp.12778 · Cited by 42
Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy
Wang, J., & Ilyas, S. I. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1865308 · Cited by 39
Diverse functions of apolipoprotein A-I in lung fibrosis
Wygrecka, M., Alexopoulos, I., Potaczek, D. P., & Schaefer, L. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00491.2022 · Cited by 37
Animal models of acute exacerbation of pulmonary fibrosis
Xu, Y., Zhang, M., Gu, H., Liu, M., Zhao, Y., Shi, Y., Wu, S., Jiang, C., Ye, X., Zhu, H., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02595-z · Cited by 43
Ku, J. C., Raiten, J., & Li, Y. (2024) · Biomedical Engineering Advances · doi:10.1016/j.bea.2024.100118 · Cited by 49
Ferroptosis in idiopathic pulmonary fibrosis: mechanisms, impact, and therapeutic opportunities
Yao, M., Liu, Z., Zhao, W., Song, S., Huang, X., & Wang, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1567994 · Cited by 61
Strookappe, B., Elfferich, M., Swigris, J. J., Verschoof, A. C., Veschakelen, J., Knevel, T., & Drent, M. (2015) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 36
Eisen, T. G., Loembé, A., Shparyk, Y. V., MacLeod, N. J., Jones, R. J., Mazurkiewicz, M., Temple, G., Dressler, H., & Bondarenko, I. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.313 · Cited by 38
New perspectives on management of idiopathic pulmonary fibrosis
Puglisi, S., Torrisi, S. E., Vindigni, V., Giuliano, R., Palmucci, S., Mulè, M., & Vancheri, C. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315624276 · Cited by 38
Role of CD248 as a potential severity marker in idiopathic pulmonary fibrosis
Bartis, D., Crowley, L., D’Souza, V., Borthwick, L. A., Fisher, A. J., Croft, A. P., Pongracz, J. E., Thompson, R. D., Langman, G., Buckley, C. D., et al. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0211-7 · Cited by 38
Hospital cost and length of stay in idiopathic pulmonary fibrosis
Mooney, J. J., Raimundo, K., Chang, E. Y., & Broder, M. S. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1282864 · Cited by 38
Inhibition of the KCa3.1 Channel Alleviates Established Pulmonary Fibrosis in a Large Animal Model
Organ, L. A., Bacci, B., Koumoundouros, E., Kimpton, W. G., Samuel, C. S., Nowell, C. J., Bradding, P., Roach, K. M., Westall, G. P., Jaffar, J., et al. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0092oc · Cited by 39
The fibrogenic actions of lung fibroblast-derived urokinase: a potential drug target in IPF
Schuliga, M. J., Jaffar, J., Harris, T., Knight, D. A., Westall, G. P., & Stewart, A. G. (2017) · Scientific Reports · doi:10.1038/srep41770 · Cited by 36
Xaubet, A., Ancochea, J., & Molina‐Molina, M. (2017) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2016.11.035 · Cited by 45
Effect of nintedanib on airway inflammation and remodeling in a murine chronic asthma model
Lee, H. Y., Hur, J., Kim, I. K., Kang, J. Y., Yoon, H. K., Lee, S. Y., Kwon, S. S., Kim, Y. K., & Rhee, C. K. (2017) · Experimental Lung Research · doi:10.1080/01902148.2017.1339141 · Cited by 40
Burden, resilience and coping in caregivers of patients with interstitial lung disease
Shah, R., Collard, H. R., & Morisset, J. (2018) · Heart & Lung · doi:10.1016/j.hrtlng.2018.03.004 · Cited by 40
Self-citationMultidisciplinary Evaluation in Patients with Lung Disease Associated with Connective Tissue Disease
Wells, A., Devaraj, A., Renzoni, E. A., & Denton, C. P. (2019) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1684020 · Cited by 36
Zulfikar, S., Mulholland, S., Adamali, H. I., & Barratt, S. L. (2020) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s228362 · Cited by 41
Chu, K.-A., Yeh, C., Kuo, F.-H., Lin, W.-R., Hsu, C.-W., Chen, T.-H., & Fu, Y.-S. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-02012-y · Cited by 38
Wright, W. A., Crowley, L., Parekh, D., Crawshaw, A., Dosanjh, D. P. S., Nightingale, P., & THICKETT, D. R. (2021) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2020-000782 · Cited by 47
Shen, L., Zhang, Y., Su, Y., Weng, D., Zhang, F., Wu, Q., Chen, T., Li, Q., Zhou, Y., Hu, Y., et al. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-71 · Cited by 48
Si-Mohamed, S. A., Nasser, M., Colevray, M., Nempont, O., Lartaud, P.-J., Vlachomitrou, A. S., Broussaud, T., Ahmad, K., Traclet, J., Cottin, V., et al. (2022) · European Radiology · doi:10.1007/s00330-021-08482-9 · Cited by 42
Self-citationWhich Patients With ARDS Benefit From Lung Biopsy?
Palakshappa, J. A., & Meyer, N. J. (2015) · CHEST Journal · doi:10.1378/chest.15-0076 · Cited by 36
Lindell, K. O., Nouraie, M. S., Klesen, M. J., Klein, S. J., Gibson, K. F., Kass, D. J., & Rosenzweig, M. Q. (2018) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2017-000272 · Cited by 38
Di, X., Chen, J., Li, Y., Wang, M., Wei, J., Li, T., Liao, B., & Luo, D. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1545 · Cited by 46
“112 The secretion of insulin like growth factor-1 by M2 macrophages also contributes to the inhibition of myofibroblast apoptosis, which is critical for the maintenance of fibrosis.”
BackgroundTu, J., Chen, X., Li, C., Liu, C., Huang, Y., Wang, X., Liang, H., & Yuan, X. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.92620 · Cited by 42
Progressive lung fibrosis: reprogramming a genetically vulnerable bronchoalveolar epithelium
Bridges, J. P., Vladar, E. K., Kurche, J. S., Krivoi, A., Stancil, I. T., Dobrinskikh, E., Hu, Y., Sasse, S. K., Lee, J. S., Blumhagen, R. Z., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci183836 · Cited by 46
Symptom‐based management of the idiopathic interstitial pneumonia
Garibaldi, B. T., & Danoff, S. K. (2015) · Respirology · doi:10.1111/resp.12649 · Cited by 40
Idiopathic Pulmonary Fibrosis: Diagnosis and Clinical Manifestations
Nakamura, Y., & Suda, T. (2015) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.4137/ccrpm.s39897 · Cited by 49
Xaubet, A., Ancochea, J., & Molina‐Molina, M. (2016) · Medicina Clínica · doi:10.1016/j.medcli.2016.11.004 · Cited by 41
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
Rinciog, C., Watkins, M., Chang, S., Maher, T. M., LeReun, C., Esser, D., & Diamantopoulos, A. (2016) · PharmacoEconomics · doi:10.1007/s40273-016-0480-2 · Cited by 39
Clinical trial research in focus: why do so many clinical trials fail in IPF?
Spagnolo, P., & Maher, T. M. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30122-4 · Cited by 39
S2k-Leitlinie Idiopathische Lungenfibrose – Update zur medikamentösen Therapie 2017
Behr, J., Günther, A., Bonella, F., Geissler, K. H., Koschel, D., Kreuter, M., Prasse, A., Schönfeld, N., Sitter, H., Müller–Quernheim, J., et al. (2017) · Pneumologie · doi:10.1055/s-0043-106160 · Cited by 37
Self-citationBeneficial effects of bile acid receptor agonists in pulmonary disease models
Comeglio, P., Morelli, A., Adorini, L., Maggi, M., & Vignozzi, L. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1385760 · Cited by 43
CCR10+ epithelial cells from idiopathic pulmonary fibrosis lungs drive remodeling
Habiel, D. M., Espindola, M. S., Jones, I. C., Coelho, A. L., Stripp, B., & Hogaboam, C. M. (2018) · JCI Insight · doi:10.1172/jci.insight.122211 · Cited by 35
Claerhout, B., Kalra, D., Mueller, C., Singh, G., Ammour, N., Meloni, L., Blomster, J., Hopley, M. J., Kafatos, G., Garvey, A., et al. (2019) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2018.12.004 · Cited by 43
Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials
Cottin, V., Azuma, A., Raghu, G., Stansen, W., Stowasser, S., Schlenker‐Herceg, R., & Kolb, M. R. J. (2019) · European Respiratory Journal · doi:10.1183/13993003.01655-2018 · Cited by 40
Self-citationYamakawa, H., Oba, T., Ohta, H., Tsukahara, Y., Kida, G., Tsumiyama, E., Nishizawa, T., Kawabe, R., Sato, S., Akasaka, K., et al. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0920-9 · Cited by 37
Soluble Thy-1 reverses lung fibrosis via its integrin-binding motif
Tan, C., Jiang, M., Wong, S. S., Espinoza, C. R., Kim, C., Li, X., Connors, E. P., & Hagood, J. S. (2019) · JCI Insight · doi:10.1172/jci.insight.131152 · Cited by 36
“Current FDA-approved medication has only decelerated the ongoing tissue remodeling, rather than halting or reversing it (1, 2).”
BackgroundChang, X. Y., Xing, L., Wang, Y., Zhou, T., Shen, L., & Jiang, H. (2020) · Nanoscale · doi:10.1039/d0nr00750a · Cited by 36
Taha, N., D’Amato, D., Hosein, K., Ranalli, T., Sergiacomi, G., Zompatori, M., & Mura, M. (2020) · Respiratory Research · doi:10.1186/s12931-020-01371-7 · Cited by 35
Crișan-Dabija, R. A., Pavel, C.-A., Popa, I. V., Țăruș, A., & Burlacu, A. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00387 · Cited by 39
Spencer, L. G., Loughenbury, M., Chaudhuri, N., Spiteri, M. A., & Parfrey, H. (2020) · ERJ Open Research · doi:10.1183/23120541.00187-2020 · Cited by 40
Ion therapy of pulmonary fibrosis by inhalation of ionic solution derived from silicate bioceramics
Chen, T., Zhang, Z., Weng, D., Lu, L., Wang, X., Xing, M., Qiu, H., Zhao, M., Shen, L., Zhou, Y., et al. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.02.013 · Cited by 49
Roberts, M. J., May, L. T., Keen, A. C., Liu, B., Lam, T., Charlton, S. J., Rosethorne, E. M., & Halls, M. L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.669227 · Cited by 37
Shumar, J. N., Chandel, A., & King, C. S. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112285 · Cited by 38
Caracena, T., Blomberg, R., Hewawasam, R. S., Fry, Z. E., Riches, D. W. H., & Magin, C. M. (2022) · Biomaterials Science · doi:10.1039/d2bm00827k · Cited by 41
Mayer, O. H., Leinonen, M., Rummey, C., Meier, T., Buyse, G., & for the DELOS Study Group (2017) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-170245 · Cited by 35
Chan, H., Weatherley, N., Johns, C., Stewart, N. J., Collier, G. J., Bianchi, S. M., & Wild, J. M. (2019) · Radiology · doi:10.1148/radiol.2019181714 · Cited by 40
No relevant pharmacokinetic drug–drug interaction between nintedanib and pirfenidone
Richeldi, L., Fletcher, S., Adamali, H., Chaudhuri, N., Wiebe, S., Wind, S., Hohl, K., Baker, A., Schlenker-Herceg, R., Stowasser, S., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01060-2018 · Cited by 34
Self-citationComparison of Pirfenidone and Nintedanib
Kim, J. S., Murray, S., Yow, E., Anstrom, K. J., Kim, H. J., Flaherty, K. R., Martinez, F. J., & Noth, I. (2024) · CHEST · doi:10.1016/j.chest.2023.11.035 · Cited by 34
Self-citationRole of dual-specificity protein phosphatase DUSP10/MKP-5 in pulmonary fibrosis
Xylourgidis, N., Min, K., Ahangari, F., Yu, G., Herazo‐Maya, J. D., Karampitsakos, Τ., Aidinis, V., Binzenhöfer, L., Bouros, D. E., Bennett, A. M., et al. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00264.2018 · Cited by 40
Chen, Y., & Fan, X. (2019) · Current Molecular Medicine · doi:10.2174/1566524019666191011160543 · Cited by 37
Mishra, S., Shah, M. I., Kumar, S. U., Kumar, D. T., Gopalakrishnan, C., Al‐Subaie, A. M., Magesh, R., Doss, C. G. P., & Kamaraj, B. (2020) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2020.10.003 · Cited by 38
Organ, L. A., Bacci, B., Koumoundouros, E., Barcham, G., Milne, M., Kimpton, W. G., Samuel, C. S., & Snibson, K. J. (2015) · BMC Pulmonary Medicine · doi:10.1186/s12890-015-0071-6 · Cited by 38
THICKETT, D. R., Kendall, C., Spencer, L. G., Screaton, N., Wallace, W. A., Pinnock, H., Bott, J., Pigram, L., Watson, S., & Millar, A. (2014) · Thorax · doi:10.1136/thoraxjnl-2014-206284 · Cited by 41
Sharp, C., McCabe, M., Hussain, M. J., Dodd, J. W., Lamb, H., Adamali, H. I., Millar, A., & Smith, D. (2016) · QJM · doi:10.1093/qjmed/hcw105 · Cited by 34
Wapenaar, M., Patel, A. S., Birring, S. S., van Domburg, R. T., Bakker, E. W. P., Vindigni, V., Sköld, C. M., Cottin, V., Vancheri, C., & Wijsenbeek, M. S. (2016) · Chronic Respiratory Disease · doi:10.1177/1479972316674425 · Cited by 40
Self-citationHorimasu, Y., Ishikawa, N., Taniwaki, M., Yamaguchi, K., Hamai, K., Iwamoto, H., Ohshimo, S., Hamada, H., Hattori, N., Okada, M., et al. (2017) · BMC Medical Genetics · doi:10.1186/s12881-017-0449-9 · Cited by 38
Roberts, M. J., Broome, R., Kent, T. C., Charlton, S. J., & Rosethorne, E. M. (2018) · Respiratory Research · doi:10.1186/s12931-018-0759-2 · Cited by 38
Diverse functions of clusterin promote and protect against the development of pulmonary fibrosis
Peix, L., Evans, I., Pearce, D. R., Simpson, J. K., Maher, T. M., & McAnulty, R. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-20316-1 · Cited by 32
Targeting interleukin-13 in idiopathic pulmonary fibrosis: from promising path to dead end
Wijsenbeek, M. S., Kool, M., & Cottin, V. (2018) · European Respiratory Journal · doi:10.1183/13993003.02111-2018 · Cited by 35
Self-citationHozumi, H., Hasegawa, H., Miyashita, K., Yasui, H., Suzuki, Y., Kono, M., Karayama, M., Furuhashi, K., Hashimoto, D., Enomoto, N., et al. (2019) · Respirology · doi:10.1111/resp.13506 · Cited by 38
In-Hospital Mortality in Patients with Idiopathic Pulmonary Fibrosis: A US Cohort Study
Durheim, M. T., Judy, J., Bender, S. D., Baumer, D. L., Lucas, J. E., Robinson, S. B., Mohamedaly, O. H., Shah, B. R., Leonard, T. B., Conoscenti, C., et al. (2019) · Lung · doi:10.1007/s00408-019-00270-z · Cited by 35
Alberti, M. L., Ruiz, J. M., Fernández, M. E., Fassola, L., Caro, F. M., Buendía-Roldán, I., & Paulín, F. (2019) · Pulmonology · doi:10.1016/j.pulmoe.2019.08.007 · Cited by 37
CPAP Adherence, Mortality, and Progression-Free Survival in Interstitial Lung Disease and OSA
Adegunsoye, A., Neborak, J. M., Zhu, D., CANTRILL, B. N., Garcia, N. M., Oldham, J. M., Noth, I., Vij, R., Kuźniar, T. J., Bellam, S. K., et al. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.04.067 · Cited by 40
“Use of antifibrotic medications in idiopathic pulmonary fibrosis (IPF), the most severe form of ILD, has been shown to slow the decline in lung function; however, they do not halt or reverse fibrosis.(2,3) Furthermore, there is a paucity of Food and Drug Administration-approved therapies in numerous other forms of ILD.”
BackgroundYamamoto, Y., Yano, Y., Kuge, T., Okabe, F., Ishijima, M., Uenami, T., Kanazu, M., Akazawa, Y., Yamaguchi, T., & Mori, M. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13675 · Cited by 42
Moon, S. W., Kim, S. Y., Chung, M. P., Yoo, H., Jeong, S. H., Kim, D. S., Song, J. W., Lee, H. L., Choi, S. M., Kim, Y. W., et al. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202005-451oc · Cited by 40
Self-citationGokey, J. J., Snowball, J. M., Green, J., Waltamath, M., Spinney, J. J., Black, K. E., Hariri, L. P., Xu, Y. J., & Perl, A. T. (2021) · Thorax · doi:10.1136/thoraxjnl-2020-214986 · Cited by 34
“FDA approved nintedanib is a broad target tyrosine kinase inhibitor that blocks both PDGFA and PDGFB signaling cascades [30, 38, 39].”
BackgroundNathan, S. D., Mehta, J., Stauffer, J. L., Morgenthien, E. A., Yang, M., Limb, S. L., & Bhorade, S. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071427 · Cited by 35
Interstitial Lung Disease in 2020
Guler, S. A., & Corte, T. J. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2021.03.001 · Cited by 43
Althobiani, M. A., Evans, R., Alqahtani, J. S., Aldhahir, A. M., Russell, A., Hurst, J. R., & Porter, J. C. (2021) · ERJ Open Research · doi:10.1183/23120541.00441-2021 · Cited by 37
Salciccioli, J. D., Marshall, D. C., Goodall, R. J., Crowley, C., Shalhoub, J., PATEL, P., & Molyneaux, P. L. (2022) · ERJ Open Research · doi:10.1183/23120541.00058-2022 · Cited by 36
Lung Organoids—The Ultimate Tool to Dissect Pulmonary Diseases?
Bosáková, V., Zuani, M. D., Sládková, L., Garlíková, Z., Jose, S. S., Zelante, T., Kohoutková, M. H., & Frič, J. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.899368 · Cited by 39
“, 2014) and nintedanib (Richeldi et al., 2014), but neither are able to cure the disease and patient survival remains poor, with a median lifespan of 3.”
BackgroundHER2 drives lung fibrosis by activating a metastatic cancer signature in invasive lung fibroblasts
Liu, X., Geng, Y., Liang, J., Coelho, A. L., Yao, C., Deng, N., Wang, Y., Dai, K., Huang, G., Xie, T., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220126 · Cited by 36
“…by the FDA to slow IPF progression and both therapies have been shown to reduce the rate of decline in the forced vital capacity (King et al., 2014; Richeldi et al., 2014), neither of these agents improves lung function or reduces fibrosis, and most patients succumb or require lung transplantation…”
Self-citationAstaxanthin: A promising therapeutic agent for organ fibrosis
Li, K., Wang, W., & Xiao, W. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106657 · Cited by 40
Cathepsin K Contributes to Cavitation and Collagen Turnover in Pulmonary Tuberculosis
Kübler, A., Larsson, C., Luna, B. M., Andrade, B. B., Amaral, E. P., Urbanowski, M. E., Orandle, M. S., Bock, K. W., Ammerman, N. C., Cheung, L. S., et al. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv458 · Cited by 35
Yang, W., Pan, L., Cheng, Y., Wu, X., Tang, B. H., Zhu, H., Zhang, M., & Zhang, Y. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109409 · Cited by 42
Choi, S. M., Mo, Y., Bang, J., Ko, Y. G., Ahn, Y. H., Kim, H. Y., Koh, J., Yim, J., & Kang, H. (2023) · Respiratory Research · doi:10.1186/s12931-023-02357-x · Cited by 36
Fainberg, H. P., Moodley, Y. P., Triguero, I., Corte, T. J., Sand, J. M. B., Leeming, D. J., Karsdal, M. A., Wells, A. U., Renzoni, E. A., Mackintosh, J. A., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00147-4 · Cited by 44
Incorporating genetics into the identification and treatment of Idiopathic Pulmonary Fibrosis
Mathai, S. K., Yang, I. V., Schwarz, M. I., & Schwartz, D. A. (2015) · BMC Medicine · doi:10.1186/s12916-015-0434-0 · Cited by 37
Molecular Endotyping of Pulmonary Fibrosis
Goodwin, A. T., & Jenkins, G. R. (2015) · CHEST Journal · doi:10.1378/chest.15-1511 · Cited by 38
Treatments for idiopathic pulmonary fibrosis.
King, T. E., Noble, P. W., & Bradford, W. Z. (2014) · PubMed · doi:10.1056/nejmc1407776 · Cited by 20
Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group
Sköld, C. M., Bendstrup, E. M., Myllärniemi, M., Guðmundsson, G., Sjåheim, T., Hilberg, O., Altraja, A., Kaarteenaho, R. L., & Ferrara, G. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12571 · Cited by 38
Idiopathic Pulmonary Fibrosis in Switzerland: Diagnosis and Treatment
Funke-Chambour, M., Azzola, A., Adler, D., Barazzone‐Argiroffo, C., Benden, C., Boehler, A., Bridevaux, P., Brutsche, M. H., Clarenbach, C. F., Hostettler, K., et al. (2017) · Respiration · doi:10.1159/000464332 · Cited by 36
Modeling Idiopathic Pulmonary Fibrosis in Humanized Severe Combined Immunodeficient Mice
Habiel, D. M., Espíndola, M. S., Coelho, A. L., & Hogaboam, C. M. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.12.020 · Cited by 36
László, V., Valkó, Z., Kovács, I., Ozsvar, J., Hoda, M. A., Klikovits, T., Lakatos, D., Czirók, A., Garay, T., Stiglbauer, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1507 · Cited by 36
Lv, X.-M., Li, M.-D., Cheng, S., Liu, B., Liu, K., Zhang, C., Xu, X., & Zhang, M. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.202 · Cited by 36
Diagnosis of asbestos-related lung diseases
Harris, E. J. A., Musk, A. W., de Klerk, N. H., Reid, A., Franklin, P., & Brims, F. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1568875 · Cited by 40
“With Asbestosis having a similar histological appearance to idiopathic pulmonary fibrosis (IPF) and with the recent trials of anti-fibrotic therapy, now licenced for IPF, slowing decline in FVC and 6-min walk distance after treatment with pirfenidone and nintedanib [83,84], there is an unmet need for these novel agent…”
BackgroundLongitudinal prediction of outcome in idiopathic pulmonary fibrosis using automated CT analysis
Jacob, J., Bartholmai, B. J., van Moorsel, C. H. M., Rajagopalan, S., Devaraj, A., van Es, H. W., Moua, T., van Beek, F. T., Clay, R., Veltkamp, M., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.02341-2018 · Cited by 35
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.